At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,200 enrolled
Drug / intervention
JARDIANCE®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance on Long Term Drug Use of JARDIANCE® Tablets in Patients With Chronic Heart Failure in Japan
In Brief
An observational study evaluating JARDIANCE® for Heart Failure. Completed, enrolled 1,200 participants across 1 site.
Detailed Summary
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesJapan
CollaboratorsEli Lilly and Company
Timeline
N/ACompletedFinished
2023202420252026
First PostedMar 2022
Enrollment StartApr 2022
Primary CompletionJun 2024
Study CompletionJun 2024
TodayJul 2026
First PostedMar 2, 2022
Enrollment StartApr 15, 2022
Primary CompletionJun 21, 2024
Study CompletionJun 28, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.3 years ago
Interventions
JARDIANCE®drug
Treatment was in accordance with the latest guidelines from The Japanese Circulation Society (JCS).